Stocks · News reference
Nautilus Biotechnology shares are trading lower. The company reported Q2 financial results.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
This SpaceX Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday
Analysts initiate coverage: Buy on Nautilus ($3.50) and SpaceX ($200); Outperform on FuelCell ($24) and Butterfly ($15); Market Perform on O’Reilly ($94).
Roth Capital Initiates Coverage On Nautilus Biotechnology with Buy Rating, Announces Price Target of $3.5
Roth Capital analyst Max Masucci initiates coverage on Nautilus Biotechnology (NASDAQ:NAUT) with a Buy rating and announces Price Target of $3.5.
Nautilus Biotechnology Files $300M Shelf Registration, Including $125M Nasdaq Common Stock ATM Offering Through TD Cowen
-SEC Filing